Novo Holdings has invested in the immuno-oncology drug developer which already counts 3SBio Group and Eisai as existing backers.

Pharmaceutical firm Novo Holdings has co-led a CHF100m ($110m) series C round for Switzerland-based immuno-oncology therapy developer Numab Therapeutics.

Healthcare-focused investment firm HBM Partners co-led the round investing together with Forbion Capital Partners’ Growth Opportunities Fund, Cormorant Asset Management, BVF Partners, RTW Investments, funds and accounts managed by BlackRock, Octagon Capital Advisors, and undisclosed existing backers.

Founded in 2011, Numab is developing antibody-based immunotherapies for chronic inflammatory diseases and cancer through an antibody discovery and engineering technology platform.

Numab will…